사회적 변화에 따라 정신질환자들의 피해망상 속에 나타난 박해자 유형변화

강승범,황인복,김한석,김승곤,김학렬,박상학,김상훈,황걸 朝鮮大學校 附設 醫學硏究所 2008 The Medical Journal of Chosun University Vol.33 No.3

Objective: The authors investigated the frequency of persecutors in persecutory delusions of the psychiatric patients who didn't undergo the arrest or traumatic injury, reside in Gwangju Jeonnam area, and were admitted to the hospital after the 5.18 prodemocracy movement in Gwangju in 1980 upward 10 years. Also this study investigated the frequency of the persecutors before and after the prodemocracy movement and in capital and Gwangju Jeonnam area. Subjects and Methods: Among the 896 patients who were admitted to department of psychiatry, Chosun University Hospital from Jan. 1. 1989 to Dec. 31. 1991, we choosed 144 patients with persecutory delusion who had lived in Gwangju Jeonnam area for 10 years after 5.18 prodemocracy movement as subjects. Persecutors were classified into 7 class: unspecified, family, neighbors, communist or spy, police or army or secret agent, impersonal, others. Results: 1) In our study, the frequency of persecutors was family, unspecified, neighbors, police or army or secret agent, impersonal, others, communist or spy in descending order. As compared to previous studies (1956-2003) including our study about frequency of persecutor at capital area and Gwangju Jeonnam area, and before and after 5.18 prodemocracy movement, 2) At capital area, in the early 1980s, police, family, neighbors, unspecified person was frequent in descending order. In the both of early 1970s, 1990s, neighbors, family, unspecified person, police was frequent in descending order. 3) At Gwangju Jeonnam area, in the early 1970s, family, unspecified person, neighbors, police was frequent in descending order. In the early 1990s, unspecified person and family, neighbors, police was frequent in descending order. 4) The police class was most frequent at capital area in the early 1980s. Conclusions: We suppose that class of persecutor in persecutory delusions of psychiatric patients are changing according to social change, and frequency of police class was decreasing in both of capital and Gwangju, Jeonnam area.

Polymorphism of the <i>SNAP25</i> gene is associated with symptom improvement in schizophrenic patients treated with amisulpride

Kang, Seung-Gul,Chee, Ik-Seung,Chang, Hun Soo,Na, Kyoung-Sae,Lee, Kwanghun,Lee, Jonghun Elsevier 2017 Neuroscience Letters Vol.661 No.-

<P><B>Abstract</B></P> <P>Synaptosomal-associated protein 25kDa (<I>SNAP25</I>) is a promising candidate gene related to the treatment response to antipsychotics. Thus, the present study investigated the associations between polymorphisms of <I>SNAP25</I> and the treatment response to amisulpride in patients with schizophrenia. This study enrolled 154 schizophrenic patients from six university hospitals in South Korea. All patients were assessed with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S) scale at baseline and week 6 of treatment. Additionally, 101 subjects were genotyped for the <I>rs</I>8636 and <I>rs</I>3746544 single nucleotide polymorphisms (SNPs) of <I>SNAP25</I>. The genotype frequencies of <I>rs</I>8636 SNP significantly differed between responders and non-responders, measured by PANSS total score, in additive, recessive, and overdominant models. These findings suggest that <I>SNAP25</I> might be a useful marker for predicting the response to antipsychotics. Future studies should include a larger number of subjects, a comprehensive array of <I>SNAP25</I> SNPs, and functional analyses.</P> <P><B>Highlights</B></P> <P> <UL> <LI> We investigated the genetic association between <I>SNAP25</I> and response to amisulpride. </LI> <LI> Genotype frequencies significantly differed between responders and non-responders. </LI> <LI> <I>SNAP25</I> might be a useful marker for predicting the response to antipsychotics. </LI> </UL> </P>

Comparison of Psychiatric Symptoms in Patients With Obstructive Sleep Apnea, Simple Snoring, and Normal Controls :

Kang, Jae Myeong,Cho, Seong-Jin,Lee, Yu Jin,Kim, Ji-Eun,Shin, Seung-Heon,Park, Kee Hyung,Kim, Seon Tae,Kang, Seung-Gul Ovid Technologies (Wolters Kluwer) - Lippincott Wi 2018 Psychosomatic medicine Vol.80 No.2

<P>Conclusions This study found that individuals with suspected OSA experienced more severe psychiatric symptoms than NCs and that psychiatric symptoms were more severe in the SS group than in the OSA group. The psychiatric symptoms of suspected OSA patients were associated with subjective sleep quality rather than with the apnea-hypopnea index.</P>

Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine

Kang, Seung-Gul,Lee, Heon-Jeong,Kim, Leen SAGE Publications 2009 Journal of psychopharmacology Vol.23 No.5

<P><B>Abstract</B></P><P>We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with olanzapine. The first patient showed a good response to olanzapine, but the RLS symptoms associated with olanzapine resulted in poor long-term compliance, eventually leading to frequent relapse of psychotic symptoms. The second patient exhibited sudden PLMS following olanzapine injection. The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime. The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered. The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation. Increasing the olanzapine dosage severely aggravated the symptoms of RLS. Antipsychotic-induced RLS and PLMS are not well-recognized side effects of antipsychotics, with the symptoms often misdiagnosed as psychotic agitation. These cases also suggest that the occurrence of RLS can cause noncompliance with antipsychotics in psychiatric patients, and thus aggravate their psychotic symptoms.</P>

DRD2 Genotypic and Haplotype Variation Is Associated With Improvements in Negative Symptoms After 6 Weeks’ Amisulpride Treatment

Kang, Seung-Gul,Na, Kyoung-Sae,Lee, Heon-Jeong,Chee, Ik-Seung,Lee, Kwanghun,Lee, Jonghun Wolters Kluwer Health, Inc. All rights reserved. 2015 JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY Vol.35 No.2

ABSTRACT: The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (&khgr; = 5.73, P = 0.017) and allele frequency (&khgr; = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride.

Cognitive Behavioral Therapy Using a Mobile Application Synchronizable With Wearable Devices for Insomnia Treatment: A Pilot Study

Kang, Seung-Gul,Kang, Jae Myeong,Cho, Seong-Jin,Ko, Kwang-Pil,Lee, Yu Jin,Lee, Heon-Jeong,Kim, Leen,Winkelman, John W. American Academy of Sleep Medicine 2017 Journal of clinical sleep medicine Vol.13 No.4

<P>Conclusions: Our pilot study suggested the clinical usefulness of a CBT-I-MA. We expect that our findings will lead to further development and replication studies of CBT-I-MA.</P>

Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia

Kang, Seung-Gul,Lee, Heon-Jeong,Choi, Jung-Eun,An, Hyonggin,Rhee, MinKyu,Kim, Leen John Wiley Sons, Ltd. 2009 HUMAN PSYCHOPHARMACOLOGY -CLINICAL AND EXPERIMENTA Vol.24 No.1

<B>Objectives</B><P>Data from several studies suggest that oxidative stress may play a role in the pathophysiology of tardive dyskinesia (TD). Glutathione S-transferase (GST) enzymes play important roles in protecting cells against oxidative stress. In the present study, we investigated the hypothesis that polymorphisms in genes for these detoxifying enzymes can influence susceptibility to TD in patients with schizophrenia.</P><B>Methods</B><P>The GST-M1, GST-T1, and GST-P1 loci were analyzed by polymerase chain reaction (PCR)-based methods in 83 schizophrenic patients with TD and 126 schizophrenic without TD who were matched for antipsychotic drug exposure and other relevant variables. The multifactor dimensionality reduction (MDR) approach was used to analyze gene–gene interactions.</P><B>Results</B><P>There were no significant differences in the distributions of the GST-M1, GST-T1, and GST-P1 genotypes between the TD and non-TD groups (p > 0.05). However, in comparison of the severity of TD among genotypes using Poisson regression showed that Ile/Ile genotype of GST-P1 had higher AIMS score compared to Ile/Val + Val/Val genotypes (X<SUP>2</SUP> = 7.13, p = 0.008). MDR analysis did not show a significant interaction between the three GST gene variants and susceptibility to TD (p > 0.05).</P><B>Conclusions</B><P>These results suggest that GST gene polymorphisms do not confer increased susceptibility to TD in patients with schizophrenia but TD severity might be related with GST-P1 variants. Copyright © 2008 John Wiley & Sons, Ltd.</P>

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics

Seung-Gul Kang,조서은,Kyoung-Sae Na,Chi Un Pae,조성진 대한정신약물학회 2021 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.19 No.1

Objective: The response to antipsychotics in patients with schizophrenia is still unsatisfactory. Therefore, augmentation with other antipsychotics is common in clinical situations. The purpose of this study was to evaluate the improvement of psychiatric symptoms and side effects after amisulpride add-on therapy. Methods: Forty patients with schizophrenia or schizoaffective disorder without treatment response to second-generation antipsychotics were included in this study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Korean version of Calgary Depression Scale for Schizophrenia (CDSS) at baseline, 4 weeks, and 8 weeks after the addition of amisulpride. Results: Among the 29 subjects who completed the 8-week study, 34.5% were responders according to PANSS total score. At week 8, the mean positive (p < 0.001), negative (p < 0.001), general (p < 0.001), and total (p < 0.001) PANSS scores and CDSS scores (p = 0.002) showed significant improvement compared to baseline. There was no increase in extrapyramidal side effects according to Simpson Angus Scale (p = 0.379) and Barnes Akathisia Rating Scale (p = 0.070) and no weight gain (p = 0.308) after the add-on treatment. Conclusion: The addition of amisulpride for schizophrenia patients without therapeutic response to second-generation antipsychotics is considered an effective and safe treatment. This study's results suggested that augmentation of second- generation antipsychotics with amisulpride could be a useful option for patients with schizophrenia unresponsive to second-generation antipsychotics. Further studies investigating the efficacy of amisulpride add-on therapy using placebo control are necessary to confirm these results.

Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia

Kang, Seung-Gul,Lee, Heon-Jeong,Choi, Jung-Eun,Park, Jae-Hong,Lee, Sang-Shin,Han, Changsu,Kim, Yong-Ku,Kim, Seung-Hyun,Lee, Min-Soo,Joe, Sook-Haeng,Jung, In-Kwa,Kim, Leen Blackwell Publishing Ltd 2007 Acta neuropsychiatrica Vol.19 No.6

<P>Objective</P><P>The incidence of restless legs syndrome (RLS) is presumed to be higher among people with schizophrenia who take antipsychotic medication, most of which blocks the dopamine D2 receptor. The purpose of this study was to determine whether the G-protein β<SUB>3</SUB> subunit (<I>GNB3</I>) C825T polymorphism is associated with antipsychotic-induced RLS in schizophrenia.</P><P>Methods</P><P>We examined 178 Korean patients with schizophrenia. All of the subjects were evaluated using the diagnostic criteria of the International Restless Legs Syndrome Study Group and the International Restless Legs Scale. Genotyping was performed for the C825T polymorphism in the <I>GNB3 </I>gene.</P><P>Results</P><P>The genotype distribution did not differ significantly between antipsychotic-induced RLS patients and patients who had no-RLS symptoms (<I>χ</I><SUP>2</SUP> = 4.30, <I>p </I>= 0.116). The genotypes of the C825T single-nucleotide polymorphism (SNP) were classified into two groups: C+ (CC and CT genotypes) and C– (TT genotype). The presence of the C allele (C+) was associated with an increased likelihood of RLS (<I>χ</I><SUP>2</SUP> = 4.14, <I>p </I>= 0.042; odds ratio = 2.56, 95% confidence interval = 1.02–6.47).</P><P>Conclusions</P><P>These results suggest that the GNB3 C825T SNP is associated with RLS in schizophrenia. However, confirming this association requires future larger scale studies in which the effects of medication are strictly controlled.</P>

The rs6265 Polymorphism of the BDNF Gene Is Related to Higher-Lethality Suicide Attempts in the Korean Population

Kang Seung-Gul,Lee Jong Hun,Lee Kwanghun,Kim Hee-Cheol,Seo Wan Seok,원승희 대한신경정신의학회 2020 PSYCHIATRY INVESTIGATION Vol.17 No.5

Objective Since the risk of suicide cannot be predicted by clinical symptoms alone, and suicide is known to have a genetic component, the discovery of genetic markers that can predict the lethality of suicide attempts is a clinically important topic. There have been many studies aiming to determine whether the rs6265 polymorphism of the BDNF gene is associated with suicidality; however, the results have been mixed, and there have been few studies investigating the relationship between this polymorphism and suicide attempt lethality. Methods We assessed suicide lethality in 258 individuals who had attempted suicide using the relative risk ratio (RRR) scale and by genotyping the rs6265 polymorphism of the BDNF gene. Results The RRR score for suicide attempts was higher in subjects with Met/Val and Val/Val genotypes than in that with a Met/Met genotype (p=0.015). The RRR score for suicide attempts was also higher in Val allele carriers (Met/Val+Val/Val) than in Met/Met homozygotes (p=0.006). Conclusion This study demonstrates the possibility that the rs6265 polymorphism of the BDNF gene could be used as a genetic marker to predict the lethality of suicide attempts, but more replication studies are needed for the application of this result in clinical practice.